<DOC>
	<DOC>NCT01675791</DOC>
	<brief_summary>The primary aim of this trial is to evaluate the dose-response relationship for the ALK tree AIT administered once daily in order to define a dose-range that would be suitable for at-home administration.</brief_summary>
	<brief_title>A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<criteria>A history of moderate to severe birch pollen allergy Use of symptomatic medication for treatment of birch pollen allergy Positive skin prick test to birch extract Positive specific IgE against Bet v 1 Overlapping perennial allergies History of uncontrolled asthma within the last 3 months FEV1 &lt; 70% of predicted value in adults or FEV1 &lt; 80% of predicted value in adolescents Previous or ongoing treatment with immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>